Diabesity Rounds

Tirzepatide vs semaglutide

Tirzepatide acts on GIP and GLP-1 receptors; semaglutide acts on GLP-1 receptors. Both are given for type 2 diabetes and for obesity. This page brings together our reports on each, and on studies that looked at both.

What our reports show

No report we hold compared tirzepatide with semaglutide directly, so this page cannot say which is better. The reports below each studied one drug against a comparator (intensified conventional care, placebo, or placebo/standard of care), in different patient groups. Their results should not be set side by side.

For tirzepatide, an open-label registry record sponsored by Eli Lilly enrolled 794 adults with early type 2 diabetes. At week 104, HbA1c change was -2.24 percentage points with tirzepatide and -1.45 with intensified conventional care, a difference of -0.79 (p <.001). The record does not say which drugs made up the comparator. A meta-analysis of seven studies (five randomised trials, two observational studies) reported that hsCRP fell by 34.3% and NT-proBNP by 17.6% with tirzepatide. These are biomarkers, not hospitalisation or death.

For semaglutide, a post hoc analysis of FLOW in 3533 adults with CKD and type 2 diabetes compared semaglutide 1.0 mg with placebo. At Week 104, the HbA1c difference ranged from -0.7% to -1.0% and the weight difference ranged from -2.5 kg to -4.6 kg (all p<0.0001 except the UACR <30 mg/g group, whose result was not reported) across subgroups. A registry record in 617 people with obesity-related HFpEF and type 2 diabetes reported a KCCQ Clinical Summary Score rise of 14.4 with semaglutide 2.4 mg and 7.6 with placebo at 52 weeks. Weight change was -10.2% and -3.2%.

The comparators differ (intensified conventional care, placebo, or placebo/standard of care), as do the populations (early diabetes, CKD, heart failure), doses, durations and endpoints. Several of these are registry records or post hoc analyses, and most outcomes are surrogates. Until a head-to-head trial is available, these reports should not guide a choice between the two drugs.

Written only from the reports below and checked against them. Updated 13 November 2026.

Studies that looked at both

None of our reports so far has covered a study of both. This list updates itself when one is published.

Tirzepatide

Semaglutide

For registered medical practitioners. This page summarises published research and is not advice for individual patients. Last new report 14 November 2026.